Atezolizumab
Brand: Tecentriq (global) / Atezolizumab (IN/BD)
Anticancer
PD-L1 Immune Checkpoint Inhibitor
Pharmacokinetics
| Half-life | 648 hours |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Fixed dose 1200 mg IV every 3 weeks (q21). RAW70 historical trials used 15 mg/kg. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies
Contraindications:
Severe autoimmune disease
Precautions:
Monitor thyroid, liver; treat grade ≥3 immune events with steroids
half-life ~27 days → 27×24 = 648 hours
standard dosing now = 1200 mg IV every 3 weeks
(which ≈ 1200/21 ~ 57 mg/day average)